11 – 20 of 92
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
(
- Contribution to journal › Letter
-
Mark
Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from sweden.
(
- Contribution to journal › Article
-
Mark
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.
(
- Contribution to journal › Article
-
Mark
Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial.
(
- Contribution to journal › Article
- 2013
-
Mark
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
(
- Contribution to journal › Article
-
Mark
Communication and Trust in the Care Provided to a Dying Parent: A Nationwide Study of Cancer-Bereaved Youths.
2013) In Journal of Clinical Oncology(
- Contribution to journal › Article
-
Mark
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease.
(
- Contribution to journal › Article
-
Mark
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.
(
- Contribution to journal › Article
-
Mark
Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer.
(
- Contribution to journal › Article
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article